tirzepatide and bone density Tirzepatide and osteoporosis risk: What clinicians need to know :- Medznat GLP-1s and Bone Health: What

These medications are typically considered when metformin and other treatments haven't achieved adequate glycaemic control, and are usually prescribed within a specific therapy sequence

Available at: www.medicines.org.uk National Institute for Health and Care Excellence

Hsu AY, Kuo HT, Wang YH, et al

Preclinical work with GLP-1R/GIPR/GcgR triple agonists showed that a balanced triple agonist produced greater body-weight loss than semaglutide, tirzepatide, and dual co-agonists in diet-induced obese mice, reducing weight to near-lean levels at the highest doses

[15] The therapy is used off-label based on emerging science and clinical experience